96 related articles for article (PubMed ID: 19538939)
1. Enhanced HIV-1 neutralization by a CD4-VH3-IgG1 fusion protein.
Meyuhas R; Noy H; Fishman S; Margalit A; Montefiori DC; Gross G
Biochem Biophys Res Commun; 2009 Aug; 386(2):402-6. PubMed ID: 19538939
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 neutralization by chimeric CD4-CG10 polypeptides fused to human IgG1.
Meyuhas R; Noy H; Montefiori DC; Denisova G; Gershoni JM; Gross G
Mol Immunol; 2005 May; 42(9):1099-109. PubMed ID: 15829299
[TBL] [Abstract][Full Text] [Related]
3. A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event.
McInerney TL; McLain L; Armstrong SJ; Dimmock NJ
Virology; 1997 Jul; 233(2):313-26. PubMed ID: 9217055
[TBL] [Abstract][Full Text] [Related]
4. Selection and characterization of an HIV-1 gp120-binding affibody ligand.
Wikman M; Rowcliffe E; Friedman M; Henning P; Lindholm L; Olofsson S; Ståhl S
Biotechnol Appl Biochem; 2006 Sep; 45(Pt 2):93-105. PubMed ID: 16712522
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of the gp120 superantigen-binding site on human immunoglobulins.
Karray S; Juompan L; Maroun RC; Isenberg D; Silverman GJ; Zouali M
J Immunol; 1998 Dec; 161(12):6681-8. PubMed ID: 9862697
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
Blish CA; Nedellec R; Mandaliya K; Mosier DE; Overbaugh J
AIDS; 2007 Mar; 21(6):693-702. PubMed ID: 17413690
[TBL] [Abstract][Full Text] [Related]
7. HIV inhibition by CD4 and CCR5-derived glycopeptides.
Perdomo MF; Sällberg M; Vahlne A
AIDS Res Hum Retroviruses; 2012 Sep; 28(9):1052-8. PubMed ID: 22559037
[TBL] [Abstract][Full Text] [Related]
8. Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker.
Beaumont T; Quakkelaar E; van Nuenen A; Pantophlet R; Schuitemaker H
J Virol; 2004 Jun; 78(11):5651-7. PubMed ID: 15140962
[TBL] [Abstract][Full Text] [Related]
9. Mapping the Ig superantigen-binding site of HIV-1 gp120.
Goodglick L; Zevit N; Neshat MS; Braun J
J Immunol; 1995 Dec; 155(11):5151-9. PubMed ID: 7594524
[TBL] [Abstract][Full Text] [Related]
10. Mapping the B cell superantigen binding site for HIV-1 gp120 on a V(H)3 Ig.
Neshat MN; Goodglick L; Lim K; Braun J
Int Immunol; 2000 Mar; 12(3):305-12. PubMed ID: 10700465
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin VH3 gene products: natural ligands for HIV gp120.
Berberian L; Goodglick L; Kipps TJ; Braun J
Science; 1993 Sep; 261(5128):1588-91. PubMed ID: 7690497
[TBL] [Abstract][Full Text] [Related]
12. Selective deficit in antibodies specific for the superantigen binding site of gp120 in HIV infection.
Juompan L; Lambin P; Zouali M
FASEB J; 1998 Nov; 12(14):1473-80. PubMed ID: 9806756
[TBL] [Abstract][Full Text] [Related]
13. The chimeric mouse-human anti-CD4 Fab 13B8.2 expressed in baculovirus inhibits both antigen presentation and HIV-1 promoter activation.
Bès C; Cerutti M; Briant-Longuet L; Bresson D; Peraldi-Roux S; Pugnière M; Mani JC; Pau B; Devaux C; Granier C; Devauchelle G; Chardès T
Hum Antibodies; 2001; 10(2):67-76. PubMed ID: 11673661
[TBL] [Abstract][Full Text] [Related]
14. Effects of HIV infection on VH3 (D12 idiotope) B cells in vivo.
Berberian L; Shukla J; Jefferis R; Braun J
J Acquir Immune Defic Syndr (1988); 1994 Jul; 7(7):641-6. PubMed ID: 8207642
[TBL] [Abstract][Full Text] [Related]
15. Combining human antisera to human leukocyte antigens, HIVgp120 and 70 kDa heat shock protein results in broadly neutralizing activity to HIV-1.
Babaahmady K; Bergmeier LA; Lehner T
AIDS; 2008 Jul; 22(11):1267-76. PubMed ID: 18580605
[TBL] [Abstract][Full Text] [Related]
16. Moesin is required for HIV-1-induced CD4-CXCR4 interaction, F-actin redistribution, membrane fusion and viral infection in lymphocytes.
Barrero-Villar M; Cabrero JR; Gordón-Alonso M; Barroso-González J; Alvarez-Losada S; Muñoz-Fernández MA; Sánchez-Madrid F; Valenzuela-Fernández A
J Cell Sci; 2009 Jan; 122(Pt 1):103-13. PubMed ID: 19066282
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 gp120: a novel viral B cell superantigen.
Townsley-Fuchs J; Neshat MS; Margolin DH; Braun J; Goodglick L
Int Rev Immunol; 1997; 14(4):325-38. PubMed ID: 9186784
[TBL] [Abstract][Full Text] [Related]
18. Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth.
Huang CC; Stricher F; Martin L; Decker JM; Majeed S; Barthe P; Hendrickson WA; Robinson J; Roumestand C; Sodroski J; Wyatt R; Shaw GM; Vita C; Kwong PD
Structure; 2005 May; 13(5):755-68. PubMed ID: 15893666
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of the principal neutralization site of HIV-1 and vaccine research].
Okamoto Y; Honda M
Tanpakushitsu Kakusan Koso; 1997 May; 42(7 Suppl):1201-8. PubMed ID: 9170954
[No Abstract] [Full Text] [Related]
20. Protein minimization of the gp120 binding region of human CD4.
Sharma D; Balamurali MM; Chakraborty K; Kumaran S; Jeganathan S; Rashid U; Ingallinella P; Varadarajan R
Biochemistry; 2005 Dec; 44(49):16192-202. PubMed ID: 16331979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
